Vaxcyte Inc. did even better than expected against competitors in the Opus-1 pivotal phase III trial that tested the safety, ...

CSL Ltd. is making one of its biggest strategic bets yet on nephrology, agreeing to pay Alentis Therapeutics SA $355 million up front and up to $1.2 billion in milestones to co-develop lixudebart, a ...

In preparing to widen the doorway for the development of ibogaine treatment, the U.S. FDA is issuing a request for information on approaches to early stage clinical trials of the schedule I controlled ...

The Nobel Assembly at Karolinska Institutet announced today that it has awarded the 2026 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning light-gated ion ...

Co. Ltd. has patented new antibody-drug conjugates comprising antibodies covalently linked to camptothecin derivatives reported to be useful for the treatment of cancer.

Celaid Therapeutics Inc. has completed the second close of its series B financing round, with participation of Shionogi & Co.

Alector Inc. and Genentech Inc. have entered into an exclusive global licensing agreement that grants the latter worldwide ...

Human genetic and RNA-silencing studies suggest that reduced Activin E-ALK7 signaling is associated with favorable metabolic outcomes, supporting investigation of the pathway as a potential target for ...

Saros Therapeutics has received its second National Cancer Institute (NCI) phase II award of approximately $2 million to ...

Xtalpi Inc. has advanced its proprietary hair loss drug program into IND-enabling studies. The program targets a ...

Inventisbio Co. Ltd. and Inventisbio LLC have synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and ...

Pfizer Inc. has disclosed new apelin receptor (APLNR) agonists reported to be useful for the treatment of obesity, diabetes, osteoporosis, cataracts, and metabolic, cardiovascular, renal and eating ...